Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From todays press release- "Rett syndrome: On track for top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial". The company has reported many times that Rett data this year.
"Ahead of commercial rollout in 2025, the company wishes to bring on board a young, talented and ambitious operational specialist to lead rollout planning, transfer to manufacturing, procurement, and full project management".
From Linkedin. Good to see.
https://www.linkedin.com/jobs/view/3765405108/?refId=UORlp1odWwWXz5zkxMf4Jw%3D%3D
Hoping if they are backing away on the enema research it is because of interest in the time release pill. I think the pill over time could make the enema treatment obsolete.
So did you pay?
Caspofungin, voriconazole and posaconazole anti-fungal activity can "potentiate" (increase effect) when added with Brilacidin.
"Previous research conducted primarily by scientists at the University of São Paulo (USP), Brazil, showed Brilacidin can potentiate several marketed antifungals, including caspofungin, voriconazole and posaconazole. Moreover, Brilacidin exhibited potent stand-alone efficacy (MIC=2.5µM) against C. neoformans – a deadly fungus that causes an estimated 220,000 cases of cryptococcal meningitis worldwide each year and for which few effective treatments exist".
http://www.ipharminc.com/press-release/2022/12/13/innovation-pharmaceuticals-reports-new-in-vivo-antifungal-data-showing-brilacidins-potential-for-treating-fungal-keratitis?rq=caspofungin%20
Reverse Rett presents the 14th Annual Reverse Rett London Gala, which is proudly sponsored by Core Marketing, Anavex Life Sciences, Blackridge Communications and KDW Financial Planning, is to be held on 10th November 2023 at the Royal College of Physicians, Regent’s Park, London.
Hmm short covering.. Go AVXL
And then there's the data - "Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration"
Outstanding is right. Many thanks PJ.
Exactly A-273 Blarcamesine as a multi-indication CNS drug. This fact has maybe been swept under.
We got this- "We are also on track within our neurodevelopmental precision medicine Rett syndrome program to release top-line data of ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the current quarter of 2023.”
Moving up after hours.
That is correct. It was one of multiple untried compounds IPIX had received in the buyout. Linking brilacidin is disingenuous.
Well it's not the first time. Hoping for more upward momentum.
Looks like it's back to the doldrums till more news.
Not the way I read the pr wording "we are also on track" We also look forward to presenting in an upcoming major publication the complete dataset of the Phase 2b/3 Alzheimer’s disease trial of ANAVEX®2-73 (blarcamesine), a potential next-generation precision medicine convenient once daily oral Alzheimer’s disease treatment,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "We are also on track within our neurodevelopmental precision medicine Rett syndrome program to release top-line data of ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the current quarter of 2023.”
We shall see.
Agree and when you've seen the full data as Missling et al and it not be strong you wouldn't use this promising statement - "We also look forward to presenting in an upcoming major publication the complete dataset of the Phase 2b/3 Alzheimer’s disease trial of ANAVEX®2-73 (blarcamesine), a potential next-generation precision medicine convenient once daily oral Alzheimer’s disease treatment,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "
Max Lugavere on Controversial Alzheimer's Drugs and Studies
https://www.facebook.com/watch/?v=6072803119453081&extid=CL-UNK-UNK-UNK-IOS_GK0T-GK1C&ref=sharing&mibextid=v7YzmG
The December of 2022 data release showed statistical significance using odds ratios for both co-primary endpoints ADAS-Cog and ADCS-ADL. You failed to mention these data results were again reiterated during a webinar in February. Anavex team never walked back those results.
We can look at the many requests for compassionate use as a positive bell weather.
We have Jefferey Cummings MD who is on the Anavex Scientific Advisory Board as a keynote speaker. No presentation listed.
News maybe slow but most importantly it has always been positive.
The New York Times - Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report
https://www.yahoo.com/news/scientists-investigating-alzheimer-drug-faulted-150053542.html
Bea Med executing nicely might cause concerns. I look forward to progress.
It sure warms my heart to think of the kids improving so well that the families can enjoy a peaceful trip out to a restaurant. The little things in life can make a big difference.
No 268000 why say all, well now we know who the cabal is..yep
Shorts better make plans.
Near term Key Near Term Pipeline Updates:
• Alzheimer’s disease: "Full data ANAVEX®2-73-AD-004, including newly available preliminary results of surrogate biomarkers of pivotal Phase 2b/3 clinical trial. The Company intends to discuss these findings with regulatory authorities in the context of the ongoing clinical development of ANAVEX®2-73 in this indication, with the goal of providing a much-needed treatment to the millions of patients living with Alzheimer’s disease with a convenient once-daily oral treatment. The Company plans to proceed in parallel with the initiation of a confirmatory Alzheimer’s disease study."
Nothing has reportedly changed since the May9 press release.
It maybe the actual meeting is taking place in MELBOURNE Australia, if so they are 14 hrs ahead.
To your question No. My question is who wrote that?
I just happen to run across a couple submissions saying Bril is a arylamide as the patent application. Seemed an important connection
This also equates Bril as as being a arylamide-- "Brilacidin (PMX-30063) is a synthetic, nonpeptidic, small-molecule mimetic of HDPs [53,54,55,56,57,58] (Figure 1). Building on “first principles” in medicinal chemistry, rational design tools—leveraging sophisticated informatics to fine-tune physicochemical properties and structure–activity relationships [59,60,61]—enabled brilacidin (an arylamide foldamer [62,63]) to overcome the shortcomings and challenges that have complicated the clinical development of natural HDPs [64]. These include proteolytic degradation, toxicity, lack of efficacy, malabsorption, and high cost to produce. In contrast to natural HDPs, as well as other HDP analogs, brilacidin was designed de novo [65,66,67] to be much smaller, more stable, more potent, more selective, and more economical to manufacture. Brilacidin has already been successfully tested in clinical trials and shown to exhibit potent antibacterial activity in Phase 2 clinical trials for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and anti-inflammatory activity, as supported in Phase 2 clinical trials for treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. As such, brilacidin has already demonstrated HDP-like therapeutic properties in the clinic".
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916214/
Brilacidin, a non-peptide chemical mimic, is an arylamide foldamer designed to replicate the amphiphilic properties of antimicrobial peptides while solving the problems encountered by peptide-based antimicrobials. Per wikipedia.
It's not hot all over the temp around the mid-atlantic region is below average.
"A separate patent application has been submitted to the USPTO for use of Brilacidin in fungal diseases".
Work on a new fungal patent. Good going.
No doubt this could be a huge opportunity as epilepsy by itself is throughout the world. "BeaMed has successfully completed the manufacturing of its first-ever MRI compatible fiber optic probes, marking a major technical milestone in its development of an advanced laser technology with respect to shaping energy and matching it to patient specific anatomy, a novel concept that BeaMed is proving a reality resulting in a major milestone in the advancement of the StingRay System. The completion of these probes allows for comprehensive integration tests, involving the unique MRI compatible fiber optics, an MRI interface software suite, special algorithms to simplify damage estimation, and custom insertion tools, planned to commence in late June 2023".
An initial area of emphasis of the StingRay System will be for the treatment of epilepsy. Epilepsy affects millions of people worldwide, causing recurrent seizures that significantly diminish their quality of life. Traditional treatment methods, such as medication and surgery, possess limitations and may not be effective for all patients. Recognizing the critical need for innovation, BeaMed has developed an advanced laser system designed to revolutionize epilepsy treatment".
How Common Is Epilepsy?
By Mary Nolan-Pleckham, RN
Published on December 12, 2022
Medically reviewed by Smita Patel, MD
Each year, about 5 million people worldwide are diagnosed with epilepsy, a brain condition that causes repeated seizures.
World Health Organization (WHO).
It is estimated that about 1 in 100 people in the United States have active epilepsy. More than 75% of those are adults.
Hey Lemon. Agree! Merck may want a new patent since CAS is sold generic. CAS + B.
Caspofungin has a generic alternative so this could possibly incentivize Merck to do a combination trial with Brilacidin and if successful a new patent.
Possibly a competitor would be interested in the combination.
Bril disrupts the cell wall and this action coupled with fungistatic CAS make a fungicide. So both given together they have a fungicidal killer. Sounds huge.
"Taken together, BRI acts by impacting A. fumigatus calcineurin signaling and the cell wall integrity pathway converting the fungistatic action of CAS against A. fumigatus into a fungicidal drug".
Wow this thing shot straight up. Huge buys.